Economic impact of delaying or preventing AIDS in persons with HIV

American Journal of Managed Care

Volumn 5, Issue 3, 1999, Pages 289-298

  Pinkerton, Steven D ^a   Holtgrave, David R ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DISEASE COURSE; DRUG COST; HEALTH CARE COST; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; TREATMENT PLANNING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; COST OF ILLNESS; COST SAVINGS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HEALTH CARE COSTS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; QUALITY-ADJUSTED LIFE YEARS; REVERSE TRANSCRIPTASE INHIBITORS; UNITED STATES;

EID: 0033037690     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Feder HM, Milch LM. Viral load and combination therapy for human immunodeficiency virus. N Engl J Med 1997;336:959-960.
2. Anonymous. New drugs for HIV infection. Med Lett Drugs Ther 1996;38:35-38.
3. Anonymous. HIV antiviral drug guide 1998. Positively Aware January/February 1998:28-42.
4. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: A review for clinicians. JAMA 1997;277:145-153.
5. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr 1997;16:54-62.
6. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: Recommendations of an international panel. JAMA 1996;276:146-154.
7. Cameron W, Heath-Chiozzi M, Kravcik S. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 1996; Washington, DC. Abstract LB6a.
8. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl Med 1996;334:1110-1117.
9. Gulick R, Mellors J, Havlin D. Potent and sustained anti-retroviral activity of indinavir in combination with zidovudine and lamivudine. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections; January 1996; Washington, DC. Abstract LB7.
10. Laezari J, Haubrich R, Burger HV. Improved survival and decreased progression of HIV in patients treated with saquinavir (invirase SQV) plus HIVID (zalcitabine, ddC). In: Program and abstracts of the XI International Conference on AIDS; July 1996; Vancouver, British Columbia. Abstract LBB6033.
11. Anis AH, Hogg RS, Wang X, et al. The effect of attenuating CD4 decline on subsequent hospitalization: Potential benefit of viral load driven antiretroviral therapy. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 1997; Washington, DC. Abstract 263.
12. Anis AH, Hogg RS, Wang X, et al. Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy. PharmacoEcon 1998;13:697-705.
13. Domingo P, Guardiola JM, Ris J, Nolla J. The impact of new antiretroviral regimes on HIV-associated hospital admissions and deaths. AIDS 1998;12:529-543.
14. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997;11:F101-F105.
15. Pehrson P, Hejdeman B, Lidman K. New principles for treatment - How does it affect the costs for HIV care? In: Program and abstracts of the 12th World AIDS Conference; July 1998; Geneva, Switzerland. Abstract 60546.
16. Petrou S, Dooley M, Whitaker L, et al. The economic costs of caring for people with HIV infection and AIDS in England and Wales. PharmacoEcon 1996;9:332-340.
17. McMurchy D. An economic evaluation of changing HIV treatment patterns in Ontario, Canada. In: Program and abstracts of the 12th World AIDS Conference; July 1998; Geneva, Switzerland. Abstract 24129.
18. Ostrop N, Davidson W, Gill MJ. The economic impact of the change in prescribing antiretroviral therapy. In: Program and abstracts of the 12th World AIDS Conference; July 1998; Geneva, Switzerland. Abstract 24123.
19. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997;336:1531-1532.
20. Ruane PJ, Tam JT, Zakowski PC, et al. Recent advances in antiviral therapy (ARV) for HIV can result in lower total costs - 3 year analysis. In: Program and abstracts of the 12th World AIDS Conference; July 1998; Geneva, Switzerland. Abstract 24136.
21. Stansell JD, Stansell JD, Daly D, Hamel E, Lappins D. Decreased healthcare utilization costs with increased use of protease inhibitors in HIV+ patients. In: Program and abstracts of the 12th World AIDS Conference; July 1998; Geneva, Switzerland. Abstract 60578.
22. Rawlings JE, Holmes J, Belton B, Selwyn P, Freidland G. Changes in HIV/AIDS patterns of care and estimated costs at an urban medical center during the era of HAART. In: Program and abstracts of the 12th World AIDS Conference; July 1998; Geneva, Switzerland. Abstract 42430.
23. Berman DS, Wenglin BD, Moore RD, et al. The efficacy of zidovudine is time-limited. JAMA 1994;272:1001-1002.
24. Brettle RP, Wilson A, Povey S, et al. Combination therapy for HIV: The effect on inpatient activity, morbidity and mortality of a cohort of patients. Int J STD & AIDS 1998;9:80-87.
25. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
26. DeNoon DJ. Drug pricing: AIDS groups protest pricing of new DuPont drug. AIDSWeekly Plus October 5, 1998.
27. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995;15:369-390.
28. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection: An economic perspective. PharmacoEcon 1996;10:109-113.
29. Cook J, Dasbach E, Coplan P, et al. Using HIV viral RNA to estimate the cost-effectiveness of indinavir alone and in combination. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 1997; Washington, DC. Abstract 331.
30. Anis A, Spinelli JJ, Hogg RS, Montaner JSG, O'Shaughnessy MV, Schechter MT. Cost-effectiveness of protease inhibitors. In: Program and abstracts of the 12th World AIDS Conference; July 1998; Geneva, Switzerland. Abstract 24125.
31. Chancellor JV, Hill AM, Sabin CA, Simpson KN, Youle M. Modeling the cost-effectiveness of lamivudine/zidovudine combination therapy in HIV infection. PharmacoEcon 1997;12:54-66.
32. Li RW, Skolnik PR, Wong JB. The cost-effectiveness of ritonavir for advanced HIV infection. In: Program and abstracts of the Ninth Annual Meeting of the Society for Medical Decision Making; October 1997; Houston, Texas. Abstract P-60.
33. Drummond MF, Torrance G, Mason J. Cost-effectiveness league tables: More harm than good? Soc Sci Med 1993;37:33-40.
34. Pinkerton SD, Holtgrave DR. Combination antiretroviral therapies for HIV: Some economic considerations. In: Ostrow DG, Kalichman SC, eds. Psychosocial and Public Health Impacts of New HIV Therapies. New York: Plenum Press; 1999
35. Kelly JA, Otto-Salaj LL, Sikkema KJ, Pinkerton SD, Bloom FR. Implications of HIV treatment advances for behavioral research on AIDS: Protease inhibitors and new challenges in HIV secondary prevention. Health Psychol 1998;17:310-319.
36. Mellors JW. Clinical Implications of resistance and cross-resistance to HIV protease inhibitors. Infections Med 1997;(suppl):32-38.